Lin ZP, Hu XL, Chen D, Huang DB, Zou XG, Zhong H, Xu SX, Chen Y, Li XQ, Zhang J. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma. World J Gastroenterol 2024; 30(17): 2321-2331 [PMID: 38813052 DOI: 10.3748/wjg.v30.i17.2321]
Corresponding Author of This Article
Jian Zhang, Doctor, Associate Chief Physician, Department of Interventional Medicine, Zhongshan People’s Hospital, No. 2 Sun Wen East Road, Zhongshan 528400, Guangdong Province, China. wy18988583838@163.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. May 7, 2024; 30(17): 2321-2331 Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2321
Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma
Zhi-Peng Lin, Xiao-Long Hu, Du Chen, Da-Bei Huang, Xu-Gong Zou, Hai Zhong, Sheng-Xiang Xu, Yuan Chen, Xiao-Qun Li, Jian Zhang
Zhi-Peng Lin, Xiao-Long Hu, Du Chen, Da-Bei Huang, Xu-Gong Zou, Hai Zhong, Sheng-Xiang Xu, Yuan Chen, Xiao-Qun Li, Jian Zhang, Department of Interventional Medicine, Zhongshan People’s Hospital, Zhongshan 528400, Guangdong Province, China
Author contributions: Lin ZP and Zhang J conceived and designed the study; Lin ZP, Hu XL, Chen D, Huang DB, Zou XG, Zhong H, Xu SX, and Chen Y contributed to data collection and analysis; Lin ZP drafted the manuscript; Lin ZP, Li XQ, and Zhang J supervised data analysis and interpretation, revised the manuscript, and gave final approval for the version to be published; and all authors read and approved the final manuscript.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of Zhongshan People’s Hospital (Approval No. 2022-029).
Informed consent statement: Study participants were not required to give informed consent because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Data sharing statement: All data and materials are available from the corresponding author.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Jian Zhang, Doctor, Associate Chief Physician, Department of Interventional Medicine, Zhongshan People’s Hospital, No. 2 Sun Wen East Road, Zhongshan 528400, Guangdong Province, China. wy18988583838@163.com
Received: February 19, 2024 Revised: March 25, 2024 Accepted: April 9, 2024 Published online: May 7, 2024 Processing time: 76 Days and 2.2 Hours
Abstract
BACKGROUND
The advent of cutting-edge systemic therapies has driven advances in the treatment of hepatocellular carcinoma (HCC), and therapeutic strategies with multiple modes of delivery have been shown to be more efficacious than monotherapy. However, the mechanisms underlying this innovative treatment modality have not been elucidated.
AIM
To evaluate the clinical efficacy of targeted therapy plus immunotherapy combined with hepatic arterial infusion chemotherapy (HAIC) of FOLFOX in patients with unresectable HCC.
METHODS
We enrolled 53 patients with unresectable HCC who received a combination of targeted therapy, immunotherapy, and HAIC of FOLFOX between December 2020 and June 2021 and assessed the efficacy and safety of the treatment regimen.
RESULTS
The objective response rate was 60.4% (32/53), complete response was 24.5% (13/53), partial response was 35.9% (19/53), and stable disease was 39.6% (21/53). The median duration of response and median progression-free survival were 9.1 and 13.9 months, respectively. The surgical conversion rate was 34.0% (18/53), and 1-year overall survival was 83.0% without critical complicating diseases or adverse events (AEs).
CONCLUSION
The regimen of HAIC of FOLFOX, targeted therapy, and immunotherapy was curative for patients with unresectable HCC, with no serious AEs and a high rate of surgical conversion.
Core Tip: The therapeutic strategy of combining multiple modes of drug delivery for the treatment of hepatocellular carcinoma (HCC) has been shown to be more efficacious than single treatment modality, but the underlying mechanism of action has not been clarified. In this study, we observed the clinical efficacy of targeted therapy plus immunotherapy combined with FOLFOX hepatic artery infusion chemotherapy in the treatment of unresectable HCC, which provides a clinical basis for the clinical application of the combination of therapy in HCC.
